Stock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations

Stock Track

05/04

Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.

The rally is attributed to renewed market confidence following Citi analyst Yigal Nochomovitz maintaining a Buy rating and a $40 price target on the stock, despite recent adverse clinical trial data. Additionally, investor optimism is building ahead of the upcoming ASCO conference, where the company's partner Akeso Biopharma is scheduled to present overall survival data for ivonescimab from the HARMONi-6 trial, seen as a potential near-term positive catalyst.

This upward move represents a recovery from a recent sharp decline triggered by interim trial data and a weak quarterly financial report. The company also noted that final progression-free survival results from the HARMONi-3 trial are expected later this year.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1184566905"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184566905\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184566905?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184566905","market":"sg","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations","media":"Stock Track","content":"<p>Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.</p><p>The rally is attributed to renewed market confidence following Citi analyst Yigal Nochomovitz maintaining a Buy rating and a $40 price target on the stock, despite recent adverse clinical trial data. Additionally, investor optimism is building ahead of the upcoming ASCO conference, where the company's partner Akeso Biopharma is scheduled to present overall survival data for ivonescimab from the HARMONi-6 trial, seen as a potential near-term positive catalyst.</p><p>This upward move represents a recovery from a recent sharp decline triggered by interim trial data and a weak quarterly financial report. The company also noted that final progression-free survival results from the HARMONi-3 trial are expected later this year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-04 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.</p><p>The rally is attributed to renewed market confidence following Citi analyst Yigal Nochomovitz maintaining a Buy rating and a $40 price target on the stock, despite recent adverse clinical trial data. Additionally, investor optimism is building ahead of the upcoming ASCO conference, where the company's partner Akeso Biopharma is scheduled to present overall survival data for ivonescimab from the HARMONi-6 trial, seen as a potential near-term positive catalyst.</p><p>This upward move represents a recovery from a recent sharp decline triggered by interim trial data and a weak quarterly financial report. The company also noted that final progression-free survival results from the HARMONi-3 trial are expected later this year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1184566905","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184566905","pubTimestamp":1777902888,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.The rally is attributed to renewed market confidence following Citi analyst Yigal...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"个股追踪|Summit Therapeutics盘中大涨5.42%，受花旗买入评级和ASCO催化剂预期影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.The rally is attributed to renewed market confidence following Citi analyst Yigal Nochomovitz maintaining a Buy rating and a $40 price target on the stock, despite recent adverse clinical trial data. Additionally, investor optimism is building ahead of the upcoming ASCO conference, where the company's partner Akeso Biopharma is scheduled to present overall survival data for ivonescimab from the HARMONi-6 trial, seen as a potential near-term positive catalyst.This upward move represents a recovery from a recent sharp decline triggered by interim trial data and a weak quarterly financial report. The company also noted that final progression-free survival results from the HARMONi-3 trial are expected later this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}